the aid library

LIST OPTIONS

Filter

12922

Toolkit for developing a multisectoral action plan for noncommunicable diseases: module 5: evaluating the implementation of a multisectoral action plan

World Health Organization (WHO) World Health Organization (WHO) (2022) C_WHO

Key stakeholders must be involved in the planning, implementation, monitoring and evaluation of NCD plans and programmes. Within a ministry of health there will be different types of stakeholders, such as programme managers and senior managers in departments of prevention, health promotion, and hosp... more

Download (169)

View PDF (268)

Childhood respiratory disease linked to the enviroment

World Health Organization WHO (2009) CC2

Childhood Respiratory Diseases & the Environment learning objectives •To understand how the respiratory tract is affected by the environment •To describe respiratory diseases linked to the environment •To list one population-level intervention and one personal-level intervention for d... more

Download (203)

View PDF (191)

WHO training package on environmental cleaning: Evaluation methodology guide

World Health Organization WHO (2024) C_WHO

This purpose of this guide is to inform robust evaluations of the WHO training package – a package aimed at personnel whose primary role in health-care facilities is environmental cleaning, hereafter referred to as cleaners. The WHO training package – Environmental cleaning and infection prev... more

Download (196)

View PDF (324)

区域性思考: 与有非传染性疾病和精神卫生问题的人举办的非正式区域磋商所作分析 2023

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

This report includes analysis from informal regional consultations in the African Region, the Caribbean and North America, Latin America, South-East Asia Region, European Region, Eastern Mediterranean Region, alongside three forums in the Western Pacific Region. It analyses the overarching similarit... more

Download (645)

View PDF (1397)

Recommended selection criteria for procurement of malaria rapid diagnostic tests

World Health Organization WHO (2018) C_WHO

This WHO information note provides an updated list of recommended criteria for selecting RDTs for malaria, and highlights the performance of RDTs evaluated by the WHO malaria RDT product testing programme. It also provides an overview of additional considerations in the procurement of rapid tests.

Download (245)

View PDF (249)

Leprosy Programme and Transmission Assessment - Tool accompanying the Technical guidance on interruption of transmission and elimination of leprosy

World Health Organization WHO (2023) C_WHO

The Leprosy Programme and Transmission Assessment (LPTA) is an activity that is carried out by internal teams towards the end of Phase 1 (see Leprosy Elimination Framework in the Annex) when a subnational jurisdiction (typically second-tier) reaches the milestone for interruption of transmission, i.... more

Download (266)

View PDF (123)

Multi-country outbreak of cholera External Situation Report # 23, published 20 February 2025

World Health Organisation (WHO) (2025) C_WHO

Multi-country outbreak of cholera External Situation Report # 23, published 20 February 2025

Download (231)

View PDF (248)

Уход на дому за пациентами с подозрением на заражение или подтвержденным заболеванием COVID-19 и тактика ведения контактных лиц
recommended

World Health Organization WHO (2020) C_WHO

Этот документ представляет собой обновление рекомендаций «Уход на дому за пациентами с легкой формой заболевания COVID‑19 и тактика ведения контактных лиц», опубл�... more

Download (281)

View PDF (392)

Strengthening countries’ capacities to adopt and adapt evidence-based guidelines: a handbook for guideline contextualization

World Health Organization WHO (2023) C_WHO

Trustworthy, evidence-based health guidelines form the basis of national policies affecting both patients and health-care workers. Emphasizing the link between robust evidence and people’s trust in their health systems, Dr Hans Henri P. Kluge, WHO Regional Director for Europe said at the launch ev... more

Download (498)

View PDF (811)

Snakebite envenoming -- A strategy for prevention and control. Executive Summary

World Health Organization WHO (2019) C_WHO

Leaflet

External Link

The social context of schistosomiasis and its control

Brunn, B.; Aagaard-Hansen, J.; Watts, S. World Health Organization WHO (2008) C_WHO

Schistosomiasis is widely recognized as a disease that is socially determined. An understanding of the social and behavioural factors linked to disease transmission and control should play a vital role in designing policies and strategies for schistosomiasis prevention and control. To this must be a... more

Download (1308)

View PDF (2494)

Test procedures for insecticide resistance monitoring in malaria vector mosquitoes

World Health Organization WHO (2016) C_WHO

2nd edition. WHO's recommendation has not changed: the standard WHO susceptibility tests should remain a primary method by which resistance is detected. However, it was considered necessary to update the existing resistance-monitoring procedures to also highlight the need for operationally meaningfu... more

External Link

Formation sur le suivi et l’évaluation épidémiologique du traitement médicamenteux de masse pour l’élimination de la filariose lymphatique : guide des apprenants

World Health Organization WHO; Institutional research information sharing iris (2013) C_WHO

Formation sur le suivi et l’évaluation épidémiologique du traitement médicamenteux de masse pour l’élimination de la filariose lymphatique : guide des apprenants. Organisation mondiale de la Santé.

Download (527)

View PDF (656)

WHO neonatal resuscitation manikin technical specifications

World Health Organization WHO WHO (2021) CC

The United Nations Commission on Life-Saving Commodities (UNCLSC, 2012) defined 13 health products to end preventable deaths of woman and children. One of those 13 products is the neonatal resuscitator, is indispensable medical device to save newborns from asphyxia at birth. For the efficient use of... more

Download (276)

View PDF (411)

Protocol to investigate non-seasonal influenza and other emerging acute respiratory diseases

World Health Organization WHO (2018) C_WHO

Download (321)

View PDF (411)

Psychological interventions implementation manual: Integrating evidence-based psychological interventions into existing services

World Health Organization WHO (2024) C_WHO

Evidence-based psychological interventions are an important part of health, social, protection and education services and can help increase access to effective mental health treatments and progression towards universal health coverage. This manual provides managers and others responsible for plan... more

Download (217)

View PDF (259)

G20 Shared Understanding on the Importance of UHC Financing in Developing Countries: Towards Sustainable and Inclusive Growth

G20 Health and Finance Ministers G20 (2019) CC

As a deliverable of the G20 Health and Finance Ministers' Meeting on June 28, 2019, ministers confirmed their commitment to this "G20 Shared Understanding."

External Link

Diseño y validación de una encuesta solo sobre triquiasis-tracomatosa: Grupo Consultivo estratégico y técnico para enfermedades tropicales desatendidas, Grupo de trabajo sobre Monitoreo y evaluación

World Health Organization WHO (2017) C_WHO

La quincuagésima primera Asamblea de la Salud Mundial aprobó la resolución WHA51.11 en 1998, que busca la eliminación mundial del tracoma como problema de salud pública para el 2020 (1). La estrategia recomendada para lograr ese objetivo está encapsulada por las siglas "SAFE", que represent... more

Download (659)

View PDF (1706)

Framework for a national plan for monitoring and management of insecticide resistance in malaria vectors

World Health Organization (WHO) (2017) C_WHO

Effective malaria prevention is threatened by widespread and increasing vector insecticide resistance. Failure to mitigate this threat will likely result in an increased burden of disease, with significant cost implications. This new framework provides support for the development of a national insec... more

Download (437)

View PDF (660)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Уход на дому за пациентами с подозрением на заражение или подтвержденным заболеванием COVID-19 и тактика ведения контактных лиц recommended

Уход на дому за пациентами с подозрением на заражение или подтвержденным заболеванием COVID-19 и тактика ведения контактных лиц
recommended